Investing
Investing Cash Flow
Neurocrine Biosciences Investing Cash Flow decreased by 856.9% to -$506.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3664.8%, from $14.20M to -$506.20M.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
A negative value typically signals investment in future growth, while a positive value may indicate divestment or the maturity of a large investment portfolio.
Detailed definition
This metric is the net total of all cash inflows and outflows related to investing activities, including capital expendi...
Peer comparison
Most mature healthcare companies maintain a negative net investing cash flow due to ongoing R&D and infrastructure investment.
Metric ID:
net_cash_from_investingHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$90.80M | -$126.20M | -$31.60M | -$61.30M | -$115.60M | -$42.10M | -$125.90M | -$97.30M | -$201.80M | -$55.00M | -$28.20M | -$68.30M | $14.20M | -$29.00M | -$196.70M | -$52.90M | -$506.20M |
| QoQ Change | — | -39.0% | +75.0% | -94.0% | -88.6% | +63.6% | -199.0% | +22.7% | -107.4% | +72.7% | +48.7% | -142.2% | +120.8% | -304.2% | -578.3% | +73.1% | -856.9% |
| YoY Change | — | — | — | +51.4% | — | -33.2% | — | -58.7% | -74.6% | -30.6% | +77.6% | +66.2% | +125.8% | -2.8% | — | +22.5% | <-999% |
Range-$506.20M – $14.20M
CAGR+53.7%
Avg YoY Growth-320.1%
Median YoY Growth-2.8%
Investing Cash Flow at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's investing cash flow?
- Neurocrine Biosciences (NBIX) reported investing cash flow of -$506.20M in Q1 2026.
- How has Neurocrine Biosciences's investing cash flow changed year-over-year?
- Neurocrine Biosciences's investing cash flow decreased by 3664.8% year-over-year, from $14.20M to -$506.20M.
- What does investing cash flow mean?
- The net amount of cash spent on or received from investing activities.